KL-35 is a potent antibacterial agent primarily investigated for its ability to inhibit bacterial protein synthesis by targeting the ribosome. It shows strong activity against a range of Gram-positive bacteria, including drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Due to its unique mechanism of action, KL-35 is being studied as a potential candidate for treating severe infections where current antibiotics have limited efficacy. Its high selectivity for bacterial ribosomes over mammalian ones makes it a promising lead compound in the development of new anti-infective therapies with fewer side effects. Research is ongoing to optimize its pharmacokinetic properties and evaluate its potential for clinical use.